About this medicine

Treatment requires coordinated prescribing, dispensing and blood testing through the brand’s monitoring service.

Clozapine is an atypical antipsychotic used in a closely supported treatment pathway. Monitoring is part of treatment, not an administrative extra: it helps balance an important option for resistant illness against blood, cardiac, bowel and metabolic risks. The patient and treating services need a clear plan for supply and interruptions.

What is this medicine used for?

The schizophrenia licence includes inadequate response to at least two antipsychotics, including an atypical, or severe untreatable neurological reactions to other antipsychotics.

The UK licence also includes psychosis occurring during Parkinson's disease when standard treatment has failed. This uses much lower dosing than treatment-resistant schizophrenia. The American recurrent-suicidal-behaviour indication is not silently added to the UK licence, and clozapine is not an emergency rescue treatment for all suicidal thoughts.

Which warning signs need help?

Seek urgent medical assessment for fever or sore throat, chest pain, breathlessness, collapse, or a seizure. Serious blood-cell reductions and heart inflammation are recognised risks.

Report constipation promptly. Severe abdominal pain, swelling or vomiting can signal dangerous bowel obstruction and need urgent help. Do not wait for the next routine appointment.

Persistent fast pulse at rest, chest pain, breathlessness or unexplained severe fatigue can signal myocarditis or cardiomyopathy, especially early in treatment. Severe sedation, difficulty walking or talking, confusion or breathing changes may indicate toxicity even when the prescribed dose has not changed.

How do I take it safely?

For schizophrenia the label starts at 12.5 mg once or twice on day one, followed by gradual increases. Parkinson’s psychosis uses a different, much lower schedule. These are supervised protocols, not instructions to adjust a dose.

The aim is an individually effective dose reached gradually while observing blood pressure, pulse, sedation and other adverse effects. The schizophrenia label describes a usual 200–450 mg daily range, but this is not a target for everyone and must not be used as a Parkinson's-psychosis schedule.

Denzapine suspension contains 50 mg in each mL. Shake for ten seconds before use and measure the prescribed amount; if dilution is needed, its label allows water, not juice. Zaponex dissolving tablets disintegrate on the tongue and contain aspartame, which matters for phenylketonuria. Both retain clozapine monitoring and restart precautions.

What side effects should I know about?

Drowsiness, increased saliva, dizziness and constipation occur. The current leaflet also describes an observed small increase in blood-cancer risk; persistent unexplained fever, swollen glands, bruising or night sweats need review.

Drooling and constipation may coexist; more saliva does not mean that bowel movement is normal. Describe bowel habits, sleepiness and how the medicine affects ordinary activities. New fever needs assessment rather than being assumed to be an ordinary early adverse effect.

Who needs extra care with this medicine?

Important exclusions include inability to undertake blood testing, relevant bone-marrow disorders, uncontrolled epilepsy, severe organ disease and paralytic ileus.

Previous clozapine-related agranulocytosis or myocarditis is especially important to disclose. Constipation, urinary problems, glaucoma, seizures, cardiovascular illness and medicines that slow the bowel also affect risk. A specialist pathway is required for any exceptional re-exposure decision; this article does not provide a rechallenge protocol.

Can it affect my other medicines?

Tell the team about all medicines and changes in smoking or caffeine. Infection, interacting medicines and smoking cessation can require plasma-level testing and dose review.

Interactions can arise when a medicine is stopped as well as when one is started. Sedatives can add to impairment, while anticholinergic or constipating medicines can worsen dangerous bowel slowing. Inform a pharmacist that clozapine is prescribed before buying over-the-counter treatments.

What check-ups will I need?

The checked UK schedule is weekly counts for 18 weeks, fortnightly for the remainder of year one, then four-weekly if stable; testing continues for at least four weeks after stopping. Drug-concentration tests serve a separate purpose.

White-cell counts and clozapine drug concentrations answer different questions. Counts support detection of blood-cell toxicity; drug levels help assess exposure in situations such as infection, smoking changes or suspected toxicity. Neither replaces bowel review, physical-health checks or assessment of cardiac symptoms.

What about pregnancy, breastfeeding and age?

Discuss pregnancy promptly with the specialist. The checked leaflet advises against breastfeeding; babies exposed late in pregnancy may need observation.

The UK label does not establish use below 16 and advises particular caution in older adults, who may be more sensitive to hypotension, constipation and urinary retention. Pregnancy planning should involve the specialist team and maternity service; stopping suddenly can destabilise illness.

What if I miss a dose or want to stop?

An interruption longer than two days requires specialist restart advice: resuming the previous dose can be dangerous. Blood-test frequency may also change.

Tolerance to postural hypotension and fast pulse is lost quickly after interruption. That explains why restarting the old dose can cause collapse even if it was previously tolerated. Tell an admitting hospital or new care service the exact last-dose time, brand and monitoring arrangements.

How does it work?

Clozapine acts at receptors, proteins that receive chemical messages from other nerve cells. Its actions include blocking several receiving sites for dopamine and serotonin, two messengers involved in many brain functions. It also affects other types of receptor, so its effects reach across several systems used for communication.

These systems work through connected groups of cells, and no single receptor action fully explains clozapine’s benefits. Researchers still do not know exactly why it can help some people after other antipsychotic medicines, used to treat experiences such as hearing voices others cannot hear or beliefs that do not fit reality, have not helped sufficiently. Its broad range of actions also contributes to unwanted effects, which need to be considered alongside symptom changes.

How does it affect my body?

Sleepiness, drooling, weight gain and constipation can affect everyday life. Constipation requires active attention, even when blood tests are satisfactory.

Neutrophils are white blood cells that help fight infection. A serious fall is a different problem from feeling sleepy or gaining weight and may not be noticed before infection develops. Bowel slowing can also progress without being reflected in a reassuring blood count, so both kinds of monitoring are needed.

How does my body process it?

Liver enzymes, particularly CYP1A2 and CYP3A4, metabolise clozapine. Smoking changes and infection can substantially alter exposure.

Tobacco smoke—not merely the nicotine dose—affects metabolism. Stopping cigarettes or changing to vaping or nicotine replacement can therefore raise clozapine exposure. Fever or serious infection can also change clearance. The team needs to know about these changes before assuming a previously tolerated dose is still appropriate.

How do treatment options differ?

Clozapine’s registered supply and monitoring requirements distinguish it from routine oral antipsychotic prescribing. Brand changes require coordination with monitoring services.

Different clozapine brands have different monitoring services. A formulation change must preserve registration, an authorised blood result, accurate dose measurement and continuity of supply. Being able to swallow a dissolving tablet or liquid does not remove the same underlying blood and physical-health precautions.

A closer look at the science

Its receptor profile includes dopamine, serotonin, histamine, muscarinic and alpha-adrenergic effects; dopamine D2 blockade is relatively weak.

The chemical structure identifies clozapine itself, not all metabolites or formulation ingredients. Binding to histamine, muscarinic and alpha-adrenergic receptors has effects beyond psychotic symptoms; a receptor-affinity diagram cannot predict benefit or a safe individual dose.

How was this medicine developed?

The UK product information checked here was revised in February 2026. Monitoring changes in another jurisdiction do not automatically change UK requirements.

The removal of the American REMS registration programme does not remove UK brand-monitoring requirements. The editions therefore explain regulatory administration separately while retaining the shared scientific reasons for blood, bowel and cardiac surveillance.

Sources and References

  1. Clozaril 100 mg tablets — UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  2. Clozaril 25 mg and 100 mg tablets — UK patient leaflet

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  3. Clinical considerations for patients prescribed clozapine

    Scope: NHS Specialist Pharmacy Service (England); not a UK-wide commissioning or legal rule.

  4. Clozapine: potentially fatal bowel obstruction risk

    Scope: United Kingdom medicines safety.

  5. Denzapine 50 mg/mL oral suspension — UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  6. Zaponex 12.5, 25, 50, 100 and 200 mg orodispersible tablets — UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  7. Clozaril (clozapine): prescribing information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: 5.1 Severe Neutropenia; 5.3 Orthostatic Hypotension, Bradycardia, and Syncope; 5.7 Gastrointestinal Hypomotility with Severe Complications; 12.1 Mechanism of Action; 12.2 Pharmacodynamics; 12.3 Pharmacokinetics. This does not establish UK product authorisation or prescribing..

  8. NIMH: Understanding psychosis
  9. Low blood pressure: MedlinePlus Medical Encyclopedia

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top